Irene Dolz-Pérez
Research Subjects
Irene Dolz-Pérez has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Camilla Pegoraro
Príncipe Felipe Research Center
1 shared publication- Cristián Huck-Iriart
ALBA Synchrotron (Spain)
1 shared publication Esther Masiá Sanchis
Príncipe Felipe Research Center
1 shared publication- Inmaculada Conejos-Sánchez
Polymer Therapeutics Laboratory Príncipe Felipe Research Center (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, 46012, Spain; Networking Research Center on Oncology (CIBERONC), Carlos III Health Institute (IISCIII), Madrid, Spain
1 shared publication Lidia Herrera
Curapath, Av. Benjamin Franklin 19, Paterna, Valencia 46980, Spain
1 shared publication- Maria Jesus Vicent
Polymer Therapeutics Lab Príncipe Felipe Research Center (CIPF) València Spain
1 shared publication
Latest Publications
- Open Access
- 5 February 2025
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 37 (4) , 1457-1467
Multifunctional Polypeptide-Based Nanoconjugates for Targeted Mitochondrial Delivery and Nonviral Gene Therapy
Despite recent advances in nanomedicine, developing multifunctional nanocarriers capable of targeted subcellular delivery and efficient gene therapy remains a significant challenge. This study reports the design, synthesis, and evaluation of a novel multifunctional polypeptide-based nanoconjugate that addresses this gap using sequential delivery, combining mitochondrial targeting and nonviral gene therapy. We engineered a poly-l-ornithine-based, polyethylene glycol-modified carrier and introduced a novel custom-designed trivalent compound (TRV3) into the structure. TRV3, conjugated to the polypeptide carrier via a redox-sensitive disulfide linker, incorporates the well-described triphenylphosphonium moiety (TPP) for mitochondrial targeting and a Cy5 fluorophore as a model drug. The resulting nanoconjugate (C-TRV3-A) demonstrated efficient endosomal escape and mitochondrial localization. Leveraging the endosomolytic properties of C-TRV3-A, we explored its potential as a nonviral vector for gene therapy. After optimizing formulation stability using a VLC-3 anionic polypeptide coating, we developed plasmid DNA polyplexes that exhibited enhanced stability and transfection efficiency in basic and advanced triple-negative breast cancer cell culture models. This multifunctional polypeptide-based nanoconjugate represents a significant advance in the field, offering a chemically versatile platform for simultaneous subcellular targeting and gene delivery that may be used in targeted cancer treatments, among other pathologies.
- 5 February 2025
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 37 (4) , 1457-1467
Open AccessMultifunctional Polypeptide-Based Nanoconjugates for Targeted Mitochondrial Delivery and Nonviral Gene Therapy
Despite recent advances in nanomedicine, developing multifunctional nanocarriers capable of targeted subcellular delivery and efficient gene therapy remains a significant challenge. This study reports the design, synthesis, and evaluation of a novel multifunctional polypeptide-based nanoconjugate that addresses this gap using sequential delivery, combining mitochondrial targeting and nonviral gene therapy. We engineered a poly-l-ornithine-based, polyethylene glycol-modified carrier and introduced a novel custom-designed trivalent compound (TRV3) into the structure. TRV3, conjugated to the polypeptide carrier via a redox-sensitive disulfide linker, incorporates the well-described triphenylphosphonium moiety (TPP) for mitochondrial targeting and a Cy5 fluorophore as a model drug. The resulting nanoconjugate (C-TRV3-A) demonstrated efficient endosomal escape and mitochondrial localization. Leveraging the endosomolytic properties of C-TRV3-A, we explored its potential as a nonviral vector for gene therapy. After optimizing formulation stability using a VLC-3 anionic polypeptide coating, we developed plasmid DNA polyplexes that exhibited enhanced stability and transfection efficiency in basic and advanced triple-negative breast cancer cell culture models. This multifunctional polypeptide-based nanoconjugate represents a significant advance in the field, offering a chemically versatile platform for simultaneous subcellular targeting and gene delivery that may be used in targeted cancer treatments, among other pathologies.